复发或难治性多发性骨髓瘤-话题@MedSci

[GetTopicListResponse(id=2204276, encodeId=407b22042e673, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a> <a href='/topic/show?id=73d4425e0cb' target=_blank style='color:#2F92EE;'>#复发或难治性多发性骨髓瘤#</a> <a href='/topic/show?id=85fa10446166' target=_blank style='color:#2F92EE;'>#西达基奥仑赛#</a>, objectTitle=CLIN CANCER RES | FDA批准摘要：西达基奥仑赛治疗复发或难治性多发性骨髓瘤, objectType=article, longId=825535, objectId=5b99825535a3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240512/1715493300929_6145188.png, objectUrl=/article/show_article.do?id=5b99825535a3, replyNumber=0, likeNumber=97, createdTime=2024-05-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5b99825535a3, moduleTitle=CLIN CANCER RES | FDA批准摘要：西达基奥仑赛治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5b99825535a3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2199559, encodeId=4bb8219955910, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a> <a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a> <a href='/topic/show?id=bcbd384814' target=_blank style='color:#2F92EE;'>#B细胞成熟抗原#</a> <a href='/topic/show?id=73d4425e0cb' target=_blank style='color:#2F92EE;'>#复发或难治性多发性骨髓瘤#</a>, objectTitle= Front Immunol：双特异性抗体治疗复发或难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=822495, objectId=86848224950f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221201/1669967708187_4754896.jpeg, objectUrl=/article/show_article.do?id=86848224950f, replyNumber=0, likeNumber=125, createdTime=2024-04-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=86848224950f, moduleTitle= Front Immunol：双特异性抗体治疗复发或难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=86848224950f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193705, encodeId=8ae92193e058d, content=<a href='/topic/show?id=73d4425e0cb' target=_blank style='color:#2F92EE;'>#复发或难治性多发性骨髓瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a>, objectTitle=EBMT摘要: RRMM中不同BCMA CAR-T的有效性间接比较, objectType=article, longId=817278, objectId=528b81e278a3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-researcher-looking-through-the-microscope-64JFWLH.jpg, objectUrl=/article/show_article.do?id=528b81e278a3, replyNumber=0, likeNumber=73, createdTime=2024-03-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=528b81e278a3, moduleTitle=EBMT摘要: RRMM中不同BCMA CAR-T的有效性间接比较, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=528b81e278a3)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

复发或难治性多发性骨髓瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#FDA# #复发或难治性多发性骨髓瘤# #西达基奥仑赛#

CLIN CANCER RES | FDA批准摘要：西达基奥仑赛治疗复发或难治性多发性骨髓瘤

2024-05-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#荟萃分析# #双特异性抗体# #B细胞成熟抗原# #复发或难治性多发性骨髓瘤#

Front Immunol：双特异性抗体治疗复发或难治性多发性骨髓瘤的疗效和安全性

2024-04-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#复发或难治性多发性骨髓瘤# #CAR-T# #BCMA#

EBMT摘要: RRMM中不同BCMA CAR-T的有效性间接比较

2024-03-17发表于上海

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#复发或难治性多发性骨髓瘤#

科室

工具

服务